Nutrition
Vitamin B6 Pyridoxine
~10 min read9 sections
Contents (9)
Vitamin B6 (pyridoxine) is a water-soluble micronutrient essential for amino acid metabolism, neurotransmitter synthesis, hemoglobin formation, and immune function. Pyridoxal-5-phosphate (PLP), the active coenzyme form, serves as a cofactor for over 100 enzymatic reactions in intermediary metabolism. B6 deficiency is relatively uncommon in developed nations but occurs with increased frequency in malnutrition, alcoholism, malabsorption syndromes, and certain medications (isoniazid, cycloserine, penicillamine). Clinical manifestations range from dermatitis and glossitis to peripheral neuropathy and seizures in severe cases. Understanding B6 metabolism and deficiency states is essential for recognizing drug-induced deficiencies and managing nutritional disorders on board examinations.
Vitamin B6 exists in three primary dietary forms: pyridoxine (PN), pyridoxal (PL), and pyridoxamine (PM), all of which are converted to the metabolically active form pyridoxal-5-phosphate (PLP) through sequential enzymatic phosphorylation. PLP serves as an indispensable coenzyme for critical metabolic processes:
- Amino acid metabolism: PLP is the essential cofactor for transaminases (ALT, AST), which catalyze the transfer of amino groups between amino acids and α-ketoacids, enabling gluconeogenesis, urea cycle function, and interconversion of amino acids. Deficiency impairs protein metabolism and amino acid homeostasis, contributing to immunosuppression through reduced lymphocyte synthesis and function.
- Neurotransmitter synthesis: PLP is required for synthesis of serotonin (from tryptophan), dopamine (from tyrosine), GABA (from glutamate), and norepinephrine, explaining neurological manifestations of deficiency. The enzyme aromatic L-amino acid decarboxylase (AADC) requires PLP as a cofactor; its inhibition leads to impaired monoamine neurotransmitter production.
- Hemoglobin and heme synthesis: PLP-dependent aminolevulinic acid synthase (ALAS) catalyzes the first committed step of heme biosynthesis, condensing glycine and succinyl-CoA. B6 deficiency results in impaired heme production, contributing to microcytic anemia (though typically milder than iron deficiency).
- Nucleotide metabolism: Phosphorylase enzymes require PLP for glycogen breakdown and nucleotide synthesis, affecting energy availability and nucleic acid metabolism critical for rapidly dividing cells (immune cells, red blood cells).
- Sphingoid base synthesis: PLP-dependent serine palmitoyltransferase initiates sphingosine synthesis, essential for myelin formation in the nervous system.
- Homocysteine metabolism: PLP is a cofactor for cystathionine β-synthase and cystathionine γ-lyase, catalyzing the transsulfuration pathway that converts homocysteine to cysteine. B6 deficiency impairs this critical pathway, allowing homocysteine accumulation with attendant vascular complications.
- Immune function: PLP deficiency reduces IL-2 production by T lymphocytes and impairs antibody formation, explaining the immunosuppressive effects of B6 deficiency and its role in infection susceptibility.
- Drug interactions at P450: Certain medications interfere with PLP synthesis or increase PLP degradation/urinary losses, creating drug-induced deficiency states independent of dietary intake.
- Inadequate dietary intake: Malnutrition, restricted diets, or poverty-associated poor nutrition; pyridoxine is found in poultry, fish, potatoes, chickpeas, and bananas, so deficiency develops over months of inadequate intake.
- Alcoholism: Ethanol impairs hepatic storage and metabolism of PLP; alcoholics frequently develop B6 deficiency as part of broader micronutrient malnutrition. Alcohol also increases urinary losses and interferes with pyridoxine absorption.
- Malabsorption syndromes: Celiac disease, inflammatory bowel disease (Crohn's disease, ulcerative colitis), tropical sprue, post-gastrectomy states, and cystic fibrosis impair intestinal absorption of dietary pyridoxine.
- Medication-induced deficiency: Isoniazid (hydrazine derivative) directly inhibits pyridoxal kinase, blocking conversion of pyridoxine to PLP and increasing urinary PLP losses; this is the most common drug-induced B6 deficiency. Cycloserine, penicillamine, theophylline, corticosteroids, and oral contraceptives similarly impair B6 metabolism or increase urinary losses.
- Chronic kidney disease and dialysis: Reduced renal conversion of pyridoxine to PLP and increased losses during hemodialysis; dialysis patients lose significant PLP through the filter.
- Hepatic disease: Cirrhosis and advanced liver disease impair hepatic storage and metabolism of pyridoxine, reducing PLP synthesis capacity.
- Hyperemesis gravidarum and hypermetabolic states: Increased B6 requirements in pregnancy (especially with nausea/vomiting), hyperthyroidism, and fever increase demand relative to intake.
- Homocystinuria (genetic): Cystathionine β-synthase deficiency may partially respond to high-dose pyridoxine if the enzyme retains some PLP-binding capacity.
- Carpal tunnel syndrome: May be associated with B6 deficiency and may respond to supplementation (though evidence is debated).
The clinical spectrum ranges from subtle biochemical abnormalities to severe neuropsychiatric and dermatologic manifestations:
- Dermatitis: Seborrheic dermatitis-like rash affecting the face, ears, and trunk; glossitis and cheilitis (inflamed, cracked lips) with magenta-colored tongue and angular cheilosis (fissuring at mouth corners). These signs reflect epithelial desquamation and impaired keratinocyte turnover due to disrupted amino acid and nucleotide metabolism.
- Peripheral neuropathy: Distal, symmetric sensory and motor neuropathy develops insidiously with demyelination of peripheral nerves; characterized by paresthesias, dysesthesias, and eventually weakness and ataxia. B6 deficiency impairs myelin synthesis (via sphingoid base deficiency) and neurotransmitter production, predisposing to axonal degeneration.
- Seizures: Generalized tonic-clonic or infantile spasms occur particularly in infants with severe deficiency or genetic B6-dependent seizure disorders (rare genetic conditions where mutant enzymes have reduced PLP affinity); seizures result from depleted inhibitory neurotransmitter (GABA) synthesis.
- Irritability and mood changes: Depression, anxiety, and behavioral disturbances reflect impaired serotonin and dopamine synthesis; these are often among the earliest neuropsychiatric manifestations.
- Confusion and cognitive impairment: Encephalopathy in severe deficiency relates to impaired neurotransmitter synthesis and myelin dysfunction.
- Microcytic anemia: Mild to moderate anemia (hemoglobin typically 9-11 g/dL) with hypochromic, microcytic indices develops over months due to impaired heme synthesis; typically less severe than iron deficiency anemia.
- Immune dysfunction: Recurrent infections (bacterial and viral), poor wound healing, and impaired vaccine response reflect reduced T cell function and antibody production.
- Elevated homocysteine: Biochemical marker of deficiency reflecting impaired transsulfuration; associated with vascular inflammation and increased cardiovascular and thromboembolic risk (though B6 supplementation for homocysteine reduction has not reduced clinical events in trials).
Diagnosis combines clinical suspicion with biochemical confirmation, as clinical signs alone are nonspecific:
- Plasma PLP concentration: The most reliable indicator of B6 status. Normal values are 30-80 nmol/L (8-20 ng/mL); values <20 nmol/L (<5 ng/mL) indicate deficiency. Sensitivity and specificity approach 90% in research settings, though practical performance varies. This is the gold standard diagnostic test ordered most commonly.
- Urinary 4-pyridoxic acid (PXA) excretion: 24-hour urinary PXA reflects recent dietary intake and PLP status. Normal excretion is 1.5-8 µmol/day; low excretion indicates inadequate intake or increased utilization. This test is less commonly used clinically.
- Plasma homocysteine: Elevated homocysteine (>15 µmol/L) reflects impaired transsulfuration and indicates B6 deficiency (though nonspecific, as other factors influence homocysteine). Often measured in cardiovascular risk assessment.
- Erythrocyte aspartate aminotransferase (AST) activity coefficient: Measures the stimulation of RBC AST activity by added PLP in vitro. A coefficient >1.5 suggests deficiency (enzyme has reduced PLP binding). This functional test is specific but rarely used in routine practice.
- Clinical context and medication history: A detailed history identifying isoniazid use, malabsorption (diarrhea, steatorrhea), alcoholism, or chronic kidney disease establishes pre-test probability. In isoniazid-treated patients, B6 deficiency is sufficiently common that prophylactic supplementation is standard regardless of baseline levels.
- Associated laboratory findings: Microcytic anemia with low serum iron and normal or high ferritin may be present; elevated ALT/AST from hepatic disease or nutritional deficiency; elevated homocysteine on metabolic panel.
- Electromyography (EMG) and nerve conduction studies: Demyelinating pattern with reduced conduction velocities in symptomatic patients with peripheral neuropathy; helps confirm neuropathy severity but is nonspecific for B6 deficiency.
- Differential diagnosis: Distinguish B6 deficiency from other causes of peripheral neuropathy (B12 deficiency, folate deficiency, diabetes, chemotherapy, inherited neuropathies), anemia (iron deficiency, B12 deficiency, chronic disease), and seizures (idiopathic epilepsy, metabolic derangements, genetic seizure disorders). B6-dependent seizure disorder is a distinct genetic entity requiring high-dose pyridoxine therapy (can be diagnosed by dramatic seizure response to IV pyridoxine challenge).
Treatment depends on deficiency severity, etiology, and presence of complications:
- First-line treatment—Oral pyridoxine supplementation: Pyridoxine 50-200 mg daily for nutritional deficiency in asymptomatic or mildly symptomatic patients. Mild deficiencies typically resolve within weeks to months. For isoniazid-induced deficiency prevention, 25-50 mg daily is given prophylactically to all patients receiving isoniazid, as the risk of symptomatic deficiency is otherwise substantial (10-15% without prophylaxis). Pyridoxine is rapidly converted to PLP in liver and tissues, achieving steady-state within days.
- Severe symptomatic deficiency with neurological manifestations: Pyridoxine 100-300 mg daily in divided doses or intravenous pyridoxine 100-200 mg daily for 1-2 weeks followed by oral therapy. Seizures may require intravenous pyridoxine 100-300 mg administered slowly (risk of local irritation); in rare B6-dependent seizure disorder, much higher doses (200-500 mg daily or more) are required chronically, guided by seizure control.
- Renal disease and dialysis patients: Pyridoxine 5-10 mg daily (lower doses than nutritional deficiency due to reduced metabolic clearance and risk of accumulation); some practitioners recommend 10-25 mg daily based on individual clearance. Dialysate pyridoxine supplementation may also be added.
- Drug-induced deficiency prophylaxis: Concurrent pyridoxine with medications known to impair B6 metabolism (isoniazid, cycloserine, penicillamine) is standard practice. Isoniazid + pyridoxine 25-50 mg daily significantly reduces neuropathy incidence from ~10% to <1%.
- Homocysteinuria (B6-responsive variant): Cystathionine β-synthase deficiency may partially respond to high-dose pyridoxine 200-500 mg daily if the enzyme retains PLP-binding capacity; genetic testing and biochemical response guide therapy. Most cases require combined therapy with folate, B12, betaine, and dietary methionine restriction.
- Non-pharmacological management: Dietary counseling emphasizing pyridoxine-rich foods (poultry, fish, potatoes, chickpeas, bananas, fortified grains) is important for long-term management; in isoniazid therapy, combined dietary counseling + pharmacological supplementation provides redundancy.
- Monitoring parameters: Clinical improvement in dermatitis and neuropathy may take 4-8 weeks; reassess symptoms at 4-6 weeks and repeat plasma PLP at 6-8 weeks to confirm normalization (target >30 nmol/L). Neurological recovery in advanced peripheral neuropathy is often incomplete even with adequate supplementation due to irreversible axonal damage; early recognition prevents progression.
- Chronic peripheral neuropathy: Prolonged B6 deficiency causes demyelination followed by axonal degeneration, resulting in permanent sensory loss, weakness, and gait disturbance. This complication is largely irreversible if allowed to progress; prevention through early detection and supplementation is critical.
- Seizures: Life-threatening acute complication, particularly in infants with severe deficiency or those with genetic B6-dependent seizure disorder. Seizures refractory to conventional antiepileptic drugs should raise suspicion for B6-dependent seizure disorder; these require high-dose pyridoxine (sometimes 500+ mg daily) for control. Status epilepticus is possible without recognition and treatment.
- Wernicke-Korsakoff-like encephalopathy: Severe deficiency in alcoholics may present with acute encephalopathy, ataxia, and ophthalmoplegia (though thiamine deficiency is more common); distinguishing requires biochemical testing and may require empiric supplementation of both vitamins.
- Immune dysregulation and opportunistic infections: Chronic deficiency impairs cell-mediated and humoral immunity, predisposing to recurrent bacterial infections, poor vaccine response, and potentially opportunistic infections. This is particularly problematic in immunocompromised populations or those with chronic diseases.
- Cardiovascular complications: Persistent hyperhomocysteinemia (if inadequately treated) increases risk of atherosclerotic vascular disease, thromboembolism, and stroke; though pyridoxine supplementation has not definitively reduced cardiovascular events in trials, normalization of homocysteine is a reasonable therapeutic goal.
- Anemia complications: Secondary anemia may exacerbate cardiac ischemia or reduce oxygen delivery in patients with pre-existing cardiopulmonary disease; correction prevents these complications.
The prognosis of B6 deficiency is generally favorable with appropriate supplementation, though timing of intervention is critical:
- Early deficiency (biochemical or mild symptoms): Excellent prognosis with oral supplementation; normalization of PLP and resolution of dermatitis, glossitis, and mild neuropsychiatric symptoms typically occur within 4-8 weeks. Return to full immune function takes longer (weeks to months).
- Symptomatic neuropathy with demyelination: Prognosis is variable; sensory symptoms may improve over months with supplementation, but motor weakness and advanced axonal loss are often partially or completely irreversible. Nerve conduction studies at baseline help predict recovery potential.
- Seizure disorders: B6-dependent seizure disorder (genetic) has excellent prognosis with high-dose pyridoxine supplementation; some patients achieve complete seizure control. Nutritional B6 deficiency with seizures also typically responds well to supplementation, though seizure recurrence may occur if supplementation is discontinued.
- Long-term outcomes: Patients maintained on adequate supplementation (especially those on isoniazid or with malabsorption) have near-normal quality of life and life expectancy. Discontinuation of supplementation in high-risk patients (isoniazid therapy, chronic alcoholism, advanced renal disease) results in recurrent deficiency within weeks to months.
- Most important testable fact: Isoniazid directly inhibits pyridoxal kinase, blocking PLP synthesis; prophylactic pyridoxine 25-50 mg daily should be given concurrently with isoniazid to prevent symptomatic neuropathy.